Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
12 oct. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief...
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment
11 oct. 2022 08h00 HE
|
Vor Biopharma
-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic stem cells resulted in long-term engraftment and persistence of editing -Data presented at European...
Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters
28 sept. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the opening of its new in-house clinical...
Vor Bio to Participate in Upcoming Investor Conferences
06 sept. 2022 16h15 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update
11 août 2022 16h15 HE
|
Vor Biopharma
Initial clinical data for patients treated with Vor Bio’s engineered HSC candidate VOR33 on track for Q4 2022In-house manufacturing facility in Cambridge, MA operational in Q4 2022Data presented at...
Vor Bio to Participate in Upcoming Investor Conferences
01 août 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA
10 juin 2022 08h00 HE
|
Vor Biopharma
Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for treatment of acute myeloid leukemia Dual edited...
Vor Bio to Participate in Upcoming Investor Conferences
01 juin 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update
12 mai 2022 16h15 HE
|
Vor Biopharma
Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022Data presented at Keystone Symposia demonstrates significant advancement of novel multiplex editing...
Vor to Participate in Two Upcoming Investor Conferences
05 mai 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will...